Preserving neurological function in patients at high risk and low risk of aggressive MS

Abstract

Poster 30 (3S) 631 journals.sagepub.com/home/msj Multiple Sclerosis Journal 2024; 30: (3S) 125-680 The annualised rate of change of immunoglobulins using ofatu-mumab was a reduction of 0.17 g/L (95% CI-0.03 to 0.37) for IgG,-0.01 g/L (-0.05 to 0.03) for IgA, and 0.29 g/L (0.22-0.36) for IgM. For ocrelizumab, the rate of reduction was 0.17 g/L (95% CI-0.13-0.21) for IgG, 0.06 g/L (0.03 to 0.07) for IgA, and 0.12 g/L (0.10-0.14) for IgM. There was no significant difference in the annualized rate of change of IgG between the anti-CD20 treatments. Conclusion: Our study highlights the rate of change of immu-noglobulin reduction over time in MS patients treated with ocrelizumab and ofatumumab. The annualised rate of immuno-globulin reduction appears to be similar between the two drugs. The results demonstrate that hypogammaglobulinaemia is likely to occur in a proportion with a long enough treatment duration. The findings have implications for understanding the immuno-logical effects of these therapies and may aid clinicians in treatment selection and monitoring strategies.